Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Malaysia ETF (EWM) vs GSK plc (GSK) Price & Performance

iShares MSCI Malaysia ETFTrade
GSK plcTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Malaysia ETF vs GSK plc — how do they compare? iShares MSCI Malaysia ETF trades at $28, while GSK plc trades at $52.8 (market cap $101.34B). The key difference: GSK plc pays a 3.49% dividend while iShares MSCI Malaysia ETF pays none. Which is the better fit depends on your goals.

EWMGSK
Sector
Broad Market / FactorHealth
52-Week High
$30.42$61.18
52-Week Low
$23.49$36.20
Market Cap
$101.34B
Enterprise Value
$121.95B
Dividend Yield
3.49%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Malaysia ETF

No Aura AI signal available yet.

GSK plc

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI Malaysia ETF

EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.

Read more on EWM

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK